Skip to content

FDA quality system requirements for drugs and biologics

Oak
A sealed production line behind glass, with one vial lifted out by a fine arm and held under a ring of white light.

An organisation making a human or animal drug product must operate under the current good manufacturing practice regulations in 21 CFR Parts 210 and 211, which set the minimum standards for methods, facilities and controls used in manufacture, processing, packing or holding.1 The full weight of Part 211 attaches once material is produced for a phase 2 or phase 3 study or once the drug is lawfully marketed. Production of an investigational drug for use in a phase 1 study is exempt from Part 211, while remaining subject to the statutory requirement in 21 U.S.C. 351(a)(2)(B).1

What the regulations cover and the consequence of non-compliance

Part 210 and Part 211, together with Parts 213, 225 and 226, contain the minimum current good manufacturing practice for methods, facilities and controls used to assure that a drug meets the safety requirements of the Federal Food, Drug, and Cosmetic Act and has the identity, strength, quality and purity it purports to possess.1 Part 211 itself applies to the preparation of drug products for administration to humans or animals. Positron emission tomography drugs and medical gases as defined in § 213.3(b)(12) fall outside Part 211.2

Failure to comply with any regulation in Part 210 or Parts 211, 213, 225 and 226 renders the drug adulterated under section 501(a)(2)(B) of the act.1 The drug and the person responsible for the failure are both subject to regulatory action.1 This is the operative enforcement mechanism: a finding of CGMP non-compliance is a finding of adulteration, independent of whether the product met its release specifications.

An organisation that performs only some of the covered operations complies with the regulations applicable to those operations.1 A contract testing laboratory, a packager and a warehouse each carry the portion of the scheme that matches what they do.

From what point in development the requirements bind

The starting point is set by § 210.2(c). An investigational drug for use in a phase 1 study, as described in § 312.21(a), is subject to the statutory requirement in 21 U.S.C. 351(a)(2)(B). Its production is exempt from Part 211.1 The statutory obligation stands on its own, so phase 1 material still has to be prepared under conditions that prevent adulteration.

The exemption is conditional and it lapses. Once the investigational drug has been made available for use by or for the sponsor in a phase 2 or phase 3 study, as described in § 312.21(b) and (c), the drug for use in the phase 1 study must comply with Part 211.1 The same result follows once the drug has been lawfully marketed.1 A sponsor running a phase 1 study of a molecule already in phase 2, or already approved, therefore has no exemption for that phase 1 material.

For a sponsor building an organisation, this means the quality system described below must be operating in full by the time phase 2 supplies are made. The transition is tied to the stage of the study programme rather than to a submission date or an inspection.

The quality control unit

Part 211 requires a quality control unit with the responsibility and authority to approve or reject all of the following.2

  • components
  • drug product containers
  • closures
  • in-process materials
  • packaging material
  • labeling
  • drug products

The unit also holds the authority to review production records to assure that no errors have occurred, or that any errors that occurred have been fully investigated.2 Where manufacture, processing, packing or holding is performed under contract by another company, approval or rejection of the resulting drug product remains the responsibility of the quality control unit.2

The definition in § 210.3(b)(15) is broad. A quality control unit means any person or organisational element designated by the firm to be responsible for the duties relating to quality control.1 A small organisation may designate an individual. The regulation fixes the duties and the authority rather than the headcount.

Adequate laboratory facilities for testing and approval or rejection of the following must be available to the unit.2

  • components
  • containers
  • closures
  • packaging materials
  • in-process materials
  • drug products

The unit is responsible for approving or rejecting all procedures or specifications that bear on the identity, strength, quality and purity of the drug product.2 Its responsibilities and procedures must be in writing, and those written procedures must be followed.2

The structure differs from that of the European system. Part 211 assigns batch approval to the quality control unit as an organisational function. The regulation names no individual release authority equivalent to a Qualified Person.

Personnel and consultants

Each person engaged in the manufacture, processing, packing or holding of a drug product must have the education, training and experience, or any combination of these, to perform the assigned functions.2 Training must cover the particular operations the employee performs and current good manufacturing practice as it relates to those functions, including the CGMP regulations and the written procedures they require.2 CGMP training must be conducted by qualified individuals on a continuing basis, with sufficient frequency that employees remain familiar with the requirements that apply to them.2

Supervisors are held to a parallel standard. Each person responsible for supervising manufacture, processing, packing or holding must have the education, training and experience to perform assigned functions in a way that provides assurance that the drug product has the safety, identity, strength, quality and purity it purports to possess.2 There must be an adequate number of qualified personnel to perform and supervise these activities for each drug product.2

Personnel must wear clean clothing appropriate to their duties, and protective apparel such as head, face, hand and arm coverings must be worn as necessary to protect products from contamination.2 Only personnel authorised by supervisory personnel may enter areas designated as limited-access.2 A person shown by medical examination or supervisory observation to have an apparent illness or open lesions that may adversely affect drug product safety or quality must be excluded from direct contact with components, containers, closures, in-process materials and drug products until the condition is corrected or cleared by competent medical personnel.2 All personnel must be instructed to report health conditions that may have an adverse effect on drug products.2

Consultants advising on manufacture, processing, packing or holding must have sufficient education, training and experience to advise on the subject for which they are retained.2 Records must state the name, address and qualifications of each consultant and the type of service provided.2

Written procedures, deviations and laboratory controls

Production and process control must run on written procedures designed to assure that drug products have the identity, strength, quality and purity they purport to possess.2 Those procedures must include all requirements of subpart F. They must be drafted, reviewed and approved by the appropriate organisational units, and reviewed and approved by the quality control unit.2

Written production and process control procedures must be followed during execution and documented at the time of performance.2 Any deviation from a written procedure must be recorded and justified.2 Contemporaneous documentation is an express requirement, so records made after the fact do not satisfy the provision.

Laboratory controls follow the same pattern. Specifications, standards, sampling plans, test procedures and other laboratory control mechanisms, including any change to them, must be drafted by the appropriate organisational unit and reviewed and approved by the quality control unit.2 Deviations from them must be recorded and justified.2 Laboratory controls must include scientifically sound specifications and test procedures covering the following.2

  • acceptance of each lot within each shipment of components, containers, closures and labeling
  • conformance of in-process materials
  • conformance of drug products
  • calibration of instruments, apparatus, gauges and recording devices against an established written programme

Instruments that do not meet established specifications must not be used.2

Records, batch release and complaints

Any production, control or distribution record associated with a batch must be retained for at least one year after the batch expiration date.2 For certain OTC drug products that lack expiration dating because they meet the exemption criteria in § 211.137, the retention period is three years after distribution of the batch.2 Records for components, containers, closures and labeling follow the same periods, measured from the expiration date or from distribution of the last lot incorporating the material.2 Records must be readily available for authorised inspection at the establishment where the recorded activities occurred, and records immediately retrievable from another location by electronic means satisfy that requirement.2

Records must be maintained so that the data can be used to evaluate the quality standards of each drug product at least annually, to determine whether specifications or manufacturing or control procedures need to change.2 Written procedures for that evaluation must be established and followed, and must provide for a review of a representative number of batches and a review of complaints, recalls, returned or salvaged product and investigations conducted under § 211.192.2 Procedures must also assure that responsible officials of the firm are notified in writing of investigations under §§ 211.198, 211.204 or 211.208, of recalls, of FDA inspectional observations and of regulatory actions relating to good manufacturing practices.2

Before a batch is released or distributed, all production and control records, including packaging and labeling records, must be reviewed and approved by the quality control unit for compliance with established approved written procedures.2 Any unexplained discrepancy, including a percentage of theoretical yield outside the limits in the master production and control records, must be thoroughly investigated.2 So must the failure of a batch or any of its components to meet a specification, whether or not the batch has already been distributed.2 The investigation must extend to other batches of the same product and other products that may be associated with the failure, and a written record with conclusions and followup must be made.2

Written procedures for handling all written and oral complaints must be established and followed.2 They must provide for quality control unit review of any complaint involving possible failure to meet a specification, and a determination of whether an investigation under § 211.192 is needed.2 They must also provide for review of whether the complaint represents a serious and unexpected adverse drug experience reportable under §§ 310.305 and 514.80.2 Where no investigation is conducted, the written record must state the reason and name the responsible person making that determination.2

Biological products and tissue-based products

Parts 600 through 680, as they pertain to biological products for human use, supplement the regulations in Parts 210 and 211.1 Where an applicable regulation in Part 211 conflicts with one in those parts, the regulation specifically applicable to the drug product in question supersedes the more general one.1 A licensed biological product is therefore subject to Part 211 in full, with the biologics-specific requirements layered on top.

Owners and operators handling human cells, tissues and cellular and tissue-based products that are drugs and subject to review under a section 505 application or a biologics license application under section 351 of the Public Health Service Act are subject to the donor-eligibility and current good tissue practice procedures in Part 1271 subparts C and D. Those procedures apply in addition to Parts 210, 211, 225 and 226.1 Failure to comply with any applicable regulation in those parts renders the HCT/P adulterated under section 501(a)(2)(B).1

Questions people also ask

Does CGMP apply to drug products used in a phase 1 clinical trial?

The statutory requirement in 21 U.S.C. 351(a)(2)(B) applies to an investigational drug for use in a phase 1 study, and production of that drug is exempt from Part 211.1 The exemption ends once the investigational drug has been made available for use by or for the sponsor in a phase 2 or phase 3 study, or once the drug has been lawfully marketed.1 In either case the drug for use in the phase 1 study must comply with Part 211.1

Who may act as the quality control unit?

Section 210.3(b)(15) defines the quality control unit as any person or organisational element designated by the firm to be responsible for the duties relating to quality control.1 The unit must hold authority to approve or reject components, in-process materials, packaging, labeling and finished drug products, and to review production records.2 Its responsibilities and procedures must be set out in writing and followed.2

How long must batch records be retained under Part 211?

Production, control and distribution records associated with a batch must be kept for at least one year after the expiration date of that batch.2 For certain OTC drug products lacking expiration dating under the § 211.137 exemption criteria, the period is three years after distribution of the batch.2 Complaint records must be kept until at least one year after the product expiration date or one year after the complaint was received, whichever is longer.2

When must a failure investigation be opened?

An investigation is required for any unexplained discrepancy found during production record review, including a yield percentage outside the limits set in the master production and control records.2 It is also required where a batch or any of its components fails to meet a specification, whether or not the batch has been distributed.2 The investigation must extend to other batches and other drug products that may have been associated with the failure.2

How do the biologics regulations interact with Part 211?

The CGMP regulations in Parts 210 and 211 and the regulations in Parts 600 through 680 supplement each other.1 Where a conflict arises, the regulation specifically applicable to the drug product in question supersedes the more general one.1 A biological product licensed under section 351 of the Public Health Service Act is subject to both sets.

What are the documentation requirements for deviations?

Written production and process control procedures must be followed and documented at the time of performance, and any deviation must be recorded and justified.2 The same applies to laboratory controls: deviations from written specifications, standards, sampling plans, test procedures or other control mechanisms must be recorded and justified.2 Where a deviation involves a specification failure, the investigation requirements of § 211.192 also apply.2

Footnotes

  1. 21 CFR Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20

  2. 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33 ↩34 ↩35 ↩36 ↩37 ↩38 ↩39 ↩40 ↩41 ↩42 ↩43 ↩44 ↩45 ↩46 ↩47 ↩48 ↩49 ↩50 ↩51 ↩52

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.